A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors

Completed · Phase 1

Conditions studied: Advanced Solid Tumor

In brief

A multicentre, 2-part study to assess the safety and tolerability of once daily oral doses of AZD2171 when administered with various anticancer regimens (part A) and to confirm the tolerability of its combination with FOLFOX (part B).

Key facts

Study ID

NCT00502567

Run by

AstraZeneca

People needed

104

Starts

2005-01-01

Expected to finish

2011-06-01

Last updated by the study team

2011-07-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• histologically confirmed metastatic cancer that is not amenable to surgery or radiation therapy with curative intent
• measurable lesion by CT or other techniques according to RECIST

You may not qualify if…

• Inadequate bone marrow reserve
• history of poorly controlled hypertension

Where it is running

• Research Site — Ann Arbor, Michigan, United States
• Research Site — Detroit, Michigan, United States
• Research Site — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.